IN2014DN05772A - - Google Patents

Info

Publication number
IN2014DN05772A
IN2014DN05772A IN5772DEN2014A IN2014DN05772A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A IN 5772DEN2014 A IN5772DEN2014 A IN 5772DEN2014A IN 2014DN05772 A IN2014DN05772 A IN 2014DN05772A
Authority
IN
India
Prior art keywords
galectin
medicament
novel compounds
compounds
ligandsin
Prior art date
Application number
Other languages
English (en)
Inventor
Ulf Nilsson
Hakon Leffler
Balaram Mukhopadhyay
Vishal Rajput
Original Assignee
Galecto Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galecto Biotech Ab filed Critical Galecto Biotech Ab
Publication of IN2014DN05772A publication Critical patent/IN2014DN05772A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN5772DEN2014 2012-01-25 2013-01-24 IN2014DN05772A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152413.6A EP2620443A1 (en) 2012-01-25 2012-01-25 Novel galactoside inhibitors of galectins
PCT/EP2013/051339 WO2013110704A1 (en) 2012-01-25 2013-01-24 Novel galactoside inhibitors of galectins

Publications (1)

Publication Number Publication Date
IN2014DN05772A true IN2014DN05772A (enExample) 2015-04-10

Family

ID=47598867

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5772DEN2014 IN2014DN05772A (enExample) 2012-01-25 2013-01-24

Country Status (8)

Country Link
US (1) US9353141B2 (enExample)
EP (2) EP2620443A1 (enExample)
JP (1) JP6158840B2 (enExample)
CN (1) CN104066743B (enExample)
CA (1) CA2854986C (enExample)
ES (1) ES2559857T3 (enExample)
IN (1) IN2014DN05772A (enExample)
WO (1) WO2013110704A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
ATE390140T1 (de) 1999-11-03 2008-04-15 Bristol Myers Squibb Co Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
CA2926480A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
WO2014100703A2 (en) 2012-12-20 2014-06-26 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
US12390486B2 (en) 2012-12-20 2025-08-19 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
ES2784873T3 (es) * 2014-07-09 2020-10-01 Galecto Biotech Ab Novedoso inhibidor galactósido híbrido de galectinas
EP3250581B1 (en) * 2015-01-30 2021-01-20 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
AU2017228365B2 (en) * 2016-03-04 2021-05-27 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
JP7216634B2 (ja) * 2016-07-12 2023-02-01 ガレクト バイオテック エービー ガレクチンのα-D-ガラクトシド阻害剤
US10988502B2 (en) * 2016-07-12 2021-04-27 Galecto Biotech Ab Alpha-D-galactoside inhibitors of galectins
BR112019023722A2 (pt) 2017-05-12 2020-05-26 Galectin Sciences, Llc Compostos para a prevenção e tratamento de doenças e o uso dos mesmos
BR112020013198A2 (pt) 2017-12-29 2020-12-01 Glycomimetics, Inc. inibidores heterobifuncionais de e-selectina e galectina-3
WO2020002765A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
JP7547345B2 (ja) 2018-12-27 2024-09-09 グリコミメティクス, インコーポレイテッド ガレクチン-3阻害性c-グリコシド
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2021028323A1 (en) * 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
CN116270672A (zh) * 2023-02-27 2023-06-23 江苏科技大学 β-D-硫代葡萄糖钠盐在制备缓解或治疗急性肾损伤的药物中的应用
CZ2023132A3 (cs) 2023-04-04 2024-10-16 Ústav Chemických Procesů Av Čr, V. V. I. Komplexy ruthenia pro inhibici galektinů, způsob jejich výroby a jejich použití

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
EP2679595B1 (en) 2008-05-16 2016-12-28 Galecto Biotech AB Di-(3-deoxy-3-1H-1,2,3-triazol-1-yl)-beta-D-galacto-pyranosyl)sulfane derivatives as galectin-3 inhibitors
WO2010126435A1 (en) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−3のガラクトシド阻害剤及び肺線維症のためのその使用

Also Published As

Publication number Publication date
CN104066743B (zh) 2016-04-06
CA2854986C (en) 2019-09-17
US20140336146A1 (en) 2014-11-13
EP2620443A1 (en) 2013-07-31
EP2807176B1 (en) 2015-12-30
CN104066743A (zh) 2014-09-24
ES2559857T3 (es) 2016-02-16
JP2015504909A (ja) 2015-02-16
EP2807176A1 (en) 2014-12-03
US9353141B2 (en) 2016-05-31
WO2013110704A1 (en) 2013-08-01
CA2854986A1 (en) 2013-08-01
JP6158840B2 (ja) 2017-07-05

Similar Documents

Publication Publication Date Title
IN2014DN05772A (enExample)
AU2012214029A8 (en) Rorgammat inhibitors
MY160241A (en) 5-alkynyl-pyrimidines
EA024702B8 (ru) Новые иммуномодуляторные и противовоспалительные соединения
MD20140002A2 (ro) Indazoli
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
NZ705135A (en) Heteroaryl compounds and methods of use thereof
MX2013004491A (es) Boronatos como inhibidores de arginasa.
PH12016500225A1 (en) Novel quinoline-substituted compound
IN2014MN02459A (enExample)
PH12015501116A1 (en) New indanyloxydihydrobenzofuranylacetic acids
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
HK1211947A1 (en) Fluorinated epoxyketone-based compounds and uses thereof as proteasome inhibitors
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
UA111628C2 (uk) Композиція для боротьби з хворобою рослини та її застосування
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
MX2014004858A (es) Compuestos de 3,4-diamino-3-ciclobuten-1,2-diona disustituidos utiles en el tratamiento de patologias mediadas por quimiocinas.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX340577B (es) Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
MX349548B (es) Compuestos de tienopirimidina.
MX2014002988A (es) Proceso y composicion para inhibir la polimerizacion de compuestos de ciclopentadieno.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MX348841B (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.